Ovarian Cancer

Ovarian cancer is the most lethal gynecologic malignancy and is the fifth leading cause of death from all cancers for women[1]. It is estimated that around 140,000 women die each year from ovarian cancer worldwide[2].

Detection of ovarian cancer at an early stage is difficult, because symptoms are, if present, shared with a wide variety of other gastrointestinal, genitourinary and gynecological conditions[2]. Ovarian cancer has a high mortality rate due to the paucity of symptoms in early stages. Early detection of ovarian cancer and early detection of cancer recurrence increase the chance for survival. When the cancer is still limited to the ovaries, up to 90% can be cured with the help of surgery and chemotherapy[3].

More insight into biomarkers that play a role in the etiology of ovarian cancer will lead to better diagnostic methods for the detection of ovarian cancer. To facilitate the research in ovarian cancer, IQ Products now offers antibodies against several biomarkers, which are described to be over or under expressed in ovarian cancer.

Check our list to see whether our research antibodies will support you looking into ovarian cancer.

References

1. Terlikowska, K.M., et al., Ovarian cancer and inflammation. Part 1. Pro-inflammatory cytokines. Progress in Health Sciences, 2018. 8(1): p. 194-201.
2. Giampaolino, P., et al., Role of biomarkers for early detection of ovarian cancer recurrence. Gland Surg, 2020. 9(4): p. 1102-1111.
3. Jammal, M.P., et al., Cytokines and Prognostic Factors in Epithelial Ovarian Cancer. Clin Med Insights Oncol, 2016. 10: p. 71-6.